extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md

@@ -55,6 +55,12 @@ WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural fac
 
 Epic's AI Charting launch (Feb 2026) threatens to commoditize the ambient documentation beachhead that standalone AI companies used to establish clinical trust. Epic's 42% acute hospital market share and native EHR integration create 'good enough' dynamics where technical superiority matters less than bundled convenience. Early pilots show Epic comparable on simple notes but behind on complex specialties, suggesting the high-adoption documentation use case is splitting into commodity (Epic-captured) and premium (specialty-focused) segments. This challenges the interpretation that scribe adoption = sustainable moat—the beachhead may be rapidly commoditized by platform incumbents.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
+
+OpenEvidence represents a distinct clinical AI category from ambient scribes: clinical reasoning/decision support rather than documentation automation. While scribes (like Abridge) reached 92% adoption for documentation, OpenEvidence reached 40%+ daily physician usage for clinical reasoning at point of care. This suggests two parallel clinical AI beachheads: (1) documentation automation (ambient scribes), and (2) clinical reasoning support (OpenEvidence). The 44% physician concern rate about accuracy/misinformation despite heavy use indicates clinical reasoning AI faces persistent trust barriers that documentation AI does not.
+
 ---
 
 Relevant Notes:

domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md

@@ -23,6 +23,12 @@ The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveragin
 
 OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
+
+OpenEvidence reached 20M clinical consultations/month by January 2026 (up from 8.5M in 2025, representing 2,000%+ YoY growth). On March 10, 2026, OpenEvidence became the first AI system to reach 1M clinical consultations in a single day. The platform is now used across 10,000+ hospitals and medical centers nationwide. Valuation tripled from $3.5B to $12B in under 12 months, with a $250M Series D led by Thrive Capital and DST Global in January 2026.
+
 ---
 
 Relevant Notes:

domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md

@@ -31,6 +31,12 @@ Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series
 
 OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
+
+OpenEvidence valuation trajectory demonstrates extreme winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with a $250M Series D in January 2026. This represents the fastest capital absorption in clinical AI history, with valuation tripling while the broader market shows 35% of deals at flat or down rounds. OpenEvidence is capturing category-defining capital velocity in clinical reasoning AI, separate from the ambient scribe market.
+
 ---
 
 Relevant Notes:

domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md

@@ -23,6 +23,12 @@ The implication for AI deployment strategy: the highest-value clinical AI applic
 
 OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
+
+OpenEvidence became the first AI in history to score 100% on all parts of the USMLE, exceeding any human score on the most challenging medical licensing exam. This creates an empirical test case: OpenEvidence is now deployed at scale (20M consultations/month, 40%+ of US physicians daily) with perfect benchmark performance, yet no peer-reviewed outcomes data demonstrates whether this translates to improved patient outcomes. The absence of outcomes data at this scale represents a critical gap in validating whether benchmark performance predicts clinical impact.
+
 ---
 
 Relevant Notes:

inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md

@@ -7,13 +7,17 @@ date: 2026-01-01
 domain: health
 secondary_domains: [ai-alignment]
 format: company-announcement
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
 processed_by: vida
 processed_date: 2026-03-18
 enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -74,6 +78,18 @@ WHY ARCHIVED: Significant scale update — the existing claim understates 2026 m
 EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim
 
 
+## Key Facts
+- OpenEvidence reached 8.5M clinical consultations/month in 2025
+- OpenEvidence reached 20M clinical consultations/month by January 2026
+- OpenEvidence valuation: $3.5B → $6B → $12B in under 12 months
+- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026)
+- OpenEvidence first AI to score 100% on USMLE (all parts)
+- OpenEvidence used across 10,000+ hospitals and medical centers
+- March 10, 2026: OpenEvidence reached 1M consultations in one day
+- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk
+- 19% of physicians concerned about lack of physician oversight/explainability
+
+
 ## Key Facts
 - OpenEvidence reached 8.5M clinical consultations/month in 2025
 - OpenEvidence reached 20M clinical consultations/month by January 2026